



Sponsor Profiles

Platinum Sponsor

Ipsen UK Limited



Ipsen is a global specialty driven pharmaceutical company with a significant presence in consumer healthcare. Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in over 30 countries worldwide. The Group has more than 4,900 employees all over the world. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its field of expertise covers oncology, neurosciences and endocrinology (adult & paediatric). Ipsen's commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering neuro-endocrine tumours, prostate cancer, bladder cancer and renal cancer. Ipsen also has a significant presence in primary care. The Ipsen Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs.

Gold Sponsor

Isotopen Technologien München AG – ITM



ITM Isotopen Technologien München AG is a privately held biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radionuclides for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radionuclides and generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine cancers and bone metastases. ITM's main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.

For more information please visit: www.itm.ag



Sponsor Profiles

Silver Sponsor

Novartis



At Novartis, our mission is to discover new ways to improve and extend people's lives. We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.

We strive to change the practice of medicine. We aspire to approach things differently—to make discoveries that take medicine in new directions. We look to tomorrow to inspire us today. Never satisfied with the status quo, we imagine what's next.

As leader in oncology, Novartis offers a portfolio of more than 20 approved therapies and approximately 30 compounds in development.

We are passionate about what we do and the impact we have on patients and societies. We are Novartis, and we are reimagining medicine.

Bronze Sponsor

Intrapharm Laboratories



Intrapharm Laboratories is a UK pharmaceutical company committed in providing to the NHS well known established products with proven efficacy at the most affordable prices. We have a wide product range in several therapeutic areas including Oncology.

ZANOSAR® (streptozocin) is indicated for the systemic treatment of adult patients with inoperable, advanced or metastatic, progressive and/or symptomatic, well differentiated, G1 or G2 neuroendocrine tumours of pancreatic origin in combination with 5-Fluorouracil

ZANOSAR® based chemotherapy is an effective and important treatment option for patients with pNETs for whom there is a demonstrated survival advantage.

We look forward to seeing you.



Sponsor Profiles

Meeting Sponsor

Advanced Accelerator Applications



A Novartis Company

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company, producing and commercialising molecular nuclear medicine theragnostics. Theragnostics is a strategy that can combine a single targeting compound with different isotopes in order to deliver diagnostic or therapeutic interventions. AAA is at the forefront of developing predictive, preventive and personalised tools and procedures that have the potential to radically transform healthcare.